RDC Clinical
Brisbane, Fortitude Valley Queensland, 4006, Australia
NCT Number: NCT06267586
Examining the effects of PeptiSleep, a plant-based sleep aid, in healthy males and females with mild to moderate sleep impairment
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Brisbane, Fortitude Valley Queensland, 4006, Australia
The primary aim of this is a first in human study is to evaluate safety and establish the effective dose in males and females who experience mild to moderate sleep impairment, but who are otherwise healthy. PeptiSleep will be supplemented one hour before bed as a single oral dose of either 250mg, 500mg or 1000mg/day. A placebo group will also be included who will receive 500mg of microcrystalline cellulose.
This trial incorporates a sleep tracking element to measure sleep quality and quantity via a ring which will be worn by participants for the duration of the study. The trial will be conducted over 10 weeks, which includes a 2 week run-in period to gather baseline sleep data, followed by 8 weeks of PeptiSleep supplementation and sleep tracking.
The primary endpoint will measure safety and tolerability via adverse event reporting and incidence rate ratio between placebo and PeptiSleep from baseline to the end of the study period.
Secondary endpoints investigated during the trial will include changes sleep quantity and quality, insomnia severity, daytime sleepiness, stress and anxiety, alertness, and biochemistry markers (melatonin, serotonin, CRP, TNFα, IL-6, E/LFT).
Exploratory endpoints will include various sleep metrics measured via the wearable tracker including heart rate variability, sleep efficiency, respiratory rate, blood oxygen sensing and daily readiness score.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Plant protein hydrolysate
Placebo MCC micro-crystalline cellulose
Time frame: Day 0 to 56
Change from baseline to the end of the study period in safety via adverse event reporting and incident rate ratio between placebo and a dose range of PeptiSleep
Time frame: Day 0 to 56
Change from baseline to the end of the study period in safety including electrolytes and liver function markers via blood test
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Sleep Quality via Leeds Sleep Evaluation Questionnaire (LSEQ). The LSEQ comprises ten self-rating 100-mm-line analogue questions concerned with aspects of sleep and early morning behaviour. A visual analogue scale is used with two extreme states defined at the ends of the line (e. g. Tired = score of 0, Alert = score of 10). The subject responds by placing a vertical mark on the line to indicate his present self- evaluation.
The four subscales are as follows:
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Insomnia Severity via Insomnia Severity Index (ISI). The questionnaire has seven questions. The seven answers are added up to get a total score.
Total score categories:
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Sleep Onset Time via Consensus Sleep Diary (CSD)
Time frame: Day 0 to 56
Change from baseline to the end of the study period in self reported Sleeping Pattern and number of Disturbance as recorded using a Consensus Sleep Diary (CSD)
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Day Time Sleepiness and Nap Count via the Epworth Sleepiness Scale (ESS). The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher the propensity for daytime sleepiness
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Stress via a self reported questionnaire - Perceived Stress Scale (PSS). The questions in this scale ask about feelings and thoughts during the last month. The questionnaire asks the participant to indicate how often they felt or thought a certain way with 0 meaning never and 4 meaning very often.
PSS scores are calculated by:
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Stress via a self reported questionnaire called Profile of Mood States (POMS). The questionnaire contains 65 words that describe feelings which are rated from 0-4. Scores are calculated:
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Anxiety via Beck Anxiety Inventory (BAI) questionnaire. The BAI consists of 21 self-reported items on a four-point scale - ''not at all'' (0) to ''severely'' (3) to assess the intensity of physical and cognitive anxiety symptoms during the past week. Scores may range from 0 to 63
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Stress via Salivary cortisol test
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Alertness via Reaction Time Test
Time frame: Day 0 to 56
Change from baseline to the end of the study period in markers associated with circadian cycles - melatonin and serotonin via blood test
Time frame: Day 0 to 56
Change from baseline to the end of the study period in Inflammatory Markers such as CRP, TNF-α and IL-6 via blood test
Time frame: Day 0 to 56
Change from baseline to the end of the study sleep onset latency measured in minutes using a wearable sleep tracker
Time frame: Day 0 to 56
Change from baseline to the end of the study in total sleep time during phases of light, deep and REM sleep measured in minutes via a wearable sleep tracker
Time frame: Day 0 to 56
Change from baseline to the end of the study in blood pressure measured in mmHG
Time frame: Day 0 to 56
Change from baseline to the end of the study in heart rate measured in beats per minute using a blood pressure machine
Time frame: Day 0 to 56
Change from baseline to the end of the study in body temperature measured in Celsius using a wearable sleep tracker
Time frame: Day 0 to 56
Change from baseline to the end of the study in BMI. The BMI is calculated by dividing weight in kilograms by height in meters squared and is measured in kg/m2.
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Bedtime as an estimate of initial period intending to sleep as measured via a wearable sleep tracker
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Total time awake in minutes via a wearable sleep tracker
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Sleep quantity measured as the number of hours between bedtime and wake-up time via a wearable sleep tracker
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Sleep efficiency. Sleep efficiency is the percentage of time spent asleep while in bed. It is calculated by dividing the amount of time spent asleep (in minutes) by the total amount of time in bed (in minutes). A normal sleep efficiency is considered to be 85% or higher.
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Sleep score Sleep Score ranges 0-100.
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Nocturnal heart rate, the number of heart beats per minute while at rest via a wearable sleep tracker
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Heart Rate variability recorded as the time interval between two heartbeats in milliseconds via a wearable sleep tracker
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Blood Oxygen sensing as measured via the sleep tracking device
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in respiratory rate as measured via the sleep tracking device
Time frame: Day -12 to 0 and Day 0 to 56. Run in period will identify sleep pattern prior to supplementation
Changes over the course of the study in Daily Readiness Score Readiness Score ranges 0-100.
Nuritas Ltd
Industry
Examining the Effects of PeptiSleep, a Plant-based Sleep Aid, in Healthy Males and Females With Mild to Moderate Sleep Impairment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT04702724
Consolidation, Sleep
Chicago, Illinois, United States
View Trial DetailsNCT05378373
Psychiatric Health, Sleep
Durham, North Carolina, United States
View Trial DetailsNCT05138848
Alzheimer Disease, Alzheimer Disease, Late Onset
Pittsburgh, Pennsylvania, United States
View Trial Details